Skip to main content Skip to navigation



Key information


REPPORT: REcurrent Patellar dislocation: Personalised therapy or OpeRative Treatment?

Chief Investigator: Professor Andrew Metcalfe & Professor Toby Smith

Sponsor: University of Warwick

Funder: NIHR Health Technology Assessment Programme

Registration Number: Add registration information here


Recurrent dislocation and instability of the patella (knee cap) can be a profoundly disabling condition. Recurrent dislocations may persist for many decades causing pain, cartilage, and soft tissue injury which can lead to long-term disability. The REPPORT trial is looking to compare a physiotherapy intervention (PKT: Personalised Knee Therapy) versus surgery. Both physiotherapy and surgery are both options for treating repeated kneecap dislocations and available in the NHS, however it is not know if one is better than the other. The REPPORT trial will offer 50% of randomised patients PKT and 50% Surgery and will compare patient reported results to see if which treatment plan has the best patient outcomes.

Sample size:

276 (1:1 Ratio)

Primary outcome:

Primary Outcomes are measure 18 months post randomisation.
Clinical Effectiveness: Participant reported function at 18-months using the Knee Injury and Osteoarthritis Outcome 4-domain Score (KOOS4)
Cost Effectiveness: Base-case within trial analysis of cost per quality-adjusted life-years (cost/QALY)


1st January 2023 - 31st December 2027

Funded by NIHR: National Institute for Health and Care Research

This study is funded by the NIHR Health Technology Assessment (HTA) Programme (NIHR134398). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Contact Us

Chief Investigators: Professor Andrew Metcalfe and Professor Toby Smith

Trial Manager: Manjit Aujla

Trial Coordinator: Georgina Ray

Tel: 02476 574996

Expression of interest healthcare professionals Link opens in a new window

Link to database: opens in a new window

Follow WCTU live TwitterLink opens in a new window